Daily Market Reports | Mar 12 2024
This story features LIFE360 INC, and other companies. For more info SHARE ANALYSIS: 360
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
360 ALC ATG CAA CAJ (3) CMM CTM CUV CVN DGL DSE DSK DUG EOS EVO FFM FLT (2) GDG (2) GEM GNC GNX HVN (2) IPD (2) IR1 JLG KAR (2) KED KYP LBL LNW M7T MAQ (2) MDR (2) MEI (2) MOZ MXI NEU (2) NXD NXS NXT ORI PPG PPM (2) PPT PTM (2) QOR RED RHC (2) S32 SDR SHV SPK SPR SXL TRJ VGL WGX (2) XRO (2)
360 LIFE360 INC
Software & Services – Overnight Price: $12.20
Goldman Sachs rates ((360)) as Buy (1) –
Goldman Sachs raises its target for Life360 by 35% to $14.20 after FY23 results demonstrated significant earnings growth and management announced plans to introduce advertising for its free user base. The Buy rating is maintained.
Management's FY24 core revenue guidance seems achievable to the broker, with growth underpinned by monthly active users, International, and the ongoing blended average revenue per paying circle (ARPPC) expansion.
Successful execution on the advertising initiative could represent an inflection point in Life360’s earnings profile, in Goldman's view.
This report was published on March 4, 2024.
Target price is $14.20 Current Price is $12.20 Difference: $2
If 360 meets the Goldman Sachs target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $13.63, suggesting upside of 11.7%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 0.00 cents and EPS of 14.28 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 85.44.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1.7, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 717.6.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 0.00 cents and EPS of 31.14 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 25.4, implying annual growth of 1394.1%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 48.0.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ALC ALCIDION GROUP LIMITED
Healthcare services – Overnight Price: $0.05
Canaccord Genuity rates ((ALC)) as Buy (1) –
An in line first half result from Alcidion Group, according to Canaccord Genuity. The company reported revenues of $19.1m for the half, and $35.5m in contracted revenue for FY24.
The first half result does provide Canaccord Genuity with some confidence in Alcidion Group reaching its full year target, despite NHS procurement delays which have consistently put pressure on new business growth.
The broker does believe the announcement of several large NHS contracts could prove an inflection point for the stock, restoring investor confidence in the sustainability of growth prospects.
The Buy rating and target price of 10 cents are retained.
This report was published on February 28, 2024.
Target price is $0.10 Current Price is $0.05 Difference: $0.05
If ALC meets the Canaccord Genuity target it will return approximately 100% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 12.50.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.00.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ATG ARTICORE GROUP LIMITED
Overnight Price: $0.53
Canaccord Genuity rates ((ATG)) as Buy (1) –
Articore Group's first half result has revealed a -10% year-on-year marketplace revenue decline to $260m, while gross profit lifted 7% to $108m. Canaccord Genuity points out the first half result is an upgrade to consensus forecasts, exceeding full year earning estimates.
Canaccord Genuity considers 2023 a period of transition for the company, as it aimed to maximise profitabilty, improve unit economics, and materially reduce its operating expenditure base.
Looking ahead, the outlook from the company was weaker than expected, with Articore Group warning trading conditions look to remain soft in the near-term.
The Buy rating is retained and the target price decreases to $1.00 from $1.20.
This report was published on February 27, 2024.
Target price is $1.00 Current Price is $0.53 Difference: $0.47
If ATG meets the Canaccord Genuity target it will return approximately 89% (excluding dividends, fees and charges).
Current consensus price target is $0.63, suggesting upside of 19.5%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 132.50.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -1.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 1.00 cents and EPS of 1.50 cents.
At the last closing share price the estimated dividend yield is 1.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 35.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -0.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CAA CAPRAL LIMITED
Aluminium, Bauxite & Alumina – Overnight Price: $9.38
Taylor Collison rates ((CAA)) as Outperform (2) –
While Capral's anticipated slowdown has commenced, comments Taylor Collison, the company has still delivered $3.0m in earnings growth over 2023 despite declining revenue, in a testament to the company's more agile operations.
The company has managed to report minimal volume reversal, down just -1% on the previous year, despite a flailing residential housing sector. Taylor Collison notes 2024 will be a first indication of Capral's ability to maintain consistent profitability following its restructuring.
The Outperform rating is retained with no target price provided.
This report was published on February 27, 2024.
Current Price is $9.38. Target price not assessed.
The company's fiscal year ends in December.
Forecast for FY24:
Taylor Collison forecasts a full year FY24 dividend of 0.00 cents and EPS of 146.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.41.
Forecast for FY25:
Taylor Collison forecasts a full year FY25 dividend of 0.00 cents and EPS of 141.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.65.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CAJ CAPITOL HEALTH LIMITED
Healthcare services – Overnight Price: $0.26
Canaccord Genuity rates ((CAJ)) as Buy (1) –
Capitol Health reported a positive first half result, Canaccord Genuity suggests. Organic revenue growth of 10.2% was in line, with margin improvement ahead of expectations. The company is working well to control costs in an inflationary environment, the broker notes.
The company's strategic plan is progressing well, in Canaccord's view, with a standard operating model across all practices, and now unified clinical software across the board aimed to restore margin.
Management is also closing down unprofitable sites, aligning labor with demand, and has taken an external review to identify further cost savings in its procurement processes.
Given the health of the balance sheet and Canaccord's view of the pathway for growth with brownfield expansion and M&A, the broker does not believe a discount to valuation is warranted. Buy and 27c target retained.
This report was published on March 8, 2024.
Target price is $0.27 Current Price is $0.26 Difference: $0.015
If CAJ meets the Canaccord Genuity target it will return approximately 6% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((CAJ)) as Neutral (3) –
Capitol Health delivered a solid first half operating result, Jarden suggests, with underlying earnings ahead of estimates. Encouragingly, and contrary to FY23 updates, margins were a positive surprise, with the company demonstrating better cost control.
Capitol Health is doing well in a tough environment, the broker notes, outperforming Medicare growth rates and improving the earnings margin by some 200bps. Positively, top-line momentum has continued into the second half despite persistent challenges in the GP referral market.
With these headwinds still looming and a PE now above historical trends, Jarden views the stock as trading at fair value and retains a Neutral rating. Target rises to 27c from 26c.
This report was published on March 8, 2024.
Target price is $0.27 Current Price is $0.26 Difference: $0.015
If CAJ meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 1.00 cents and EPS of 1.00 cents.
At the last closing share price the estimated dividend yield is 3.92%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.50.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 1.00 cents and EPS of 1.30 cents.
At the last closing share price the estimated dividend yield is 3.92%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.62.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Wilsons rates ((CAJ)) as Market Weight (3) –
The first half results from Capitol Health were ahead of Wilsons and described as "excellent".
The beat stemmed from market share and a notable change in billing mix. The broker believes the business is delivering solid results from a "workmanlike set of otherwise unspectacular radiology assets".
Wilsons also notes margin improvement has been flagged and upgrades estimates by mid single-digit percentages. Market Weight retained. Target is raised to $0.27 from $0.25.
This report was published on February 29, 2024.
Target price is $0.27 Current Price is $0.26 Difference: $0.015
If CAJ meets the Wilsons target it will return approximately 6% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 1.00 cents and EPS of 1.00 cents.
At the last closing share price the estimated dividend yield is 3.92%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.50.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 1.10 cents and EPS of 1.30 cents.
At the last closing share price the estimated dividend yield is 4.31%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.62.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CMM CAPRICORN METALS LIMITED
Gold & Silver – Overnight Price: $5.00
Jarden rates ((CMM)) as Overweight (2) –
As per Jarden, Capricorn Metals has, relative to peers, enjoyed stable share price performance over the past two years.
The broker expects a track record in delivering new mining operations and a material production growth outlook should benefit the company as it heads into 2024 with an increased focus on delivery of its Mt Gibson gold project.
The broker feels Capricorn Metals is heading into the new calendar year in a strong position. The Overweight rating is retained and the target price decreases to $4.77 from $4.78.
This report was published on March 5, 2024.
Target price is $4.77 Current Price is $5.00 Difference: minus $0.23 (current price is over target).
If CMM meets the Jarden target it will return approximately minus 5% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 EPS of 26.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.16.
Forecast for FY25:
Jarden forecasts a full year FY25 EPS of 20.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 24.63.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CTM CENTAURUS METALS LIMITED
Nickel – Overnight Price: $0.28
Canaccord Genuity rates ((CTM)) as No Rating (-1) –
Canaccord Genuity places its price target and rating under review after Centaurus Metals announced the deferral of the downstream component of its upcoming DFS for the Jaguar Nickel Sulphide Project in Brazil.
Management will now revert to a more conventional sulphide concentrate production scenario, explain the analysts. Downstream production of nickel sulphate will be via pressure oxidation methods, potentially coming in a later stage 2 scenario.
Canaccord highlights much of the current DFS (concentrate then downstream) work can be utilised by this new DFS (concentrate only).
This report was published on March 5, 2024.
Current Price is $0.28. Target price not assessed.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CUV CLINUVEL PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $13.21
Wilsons rates ((CUV)) as Overweight (1) –
Clinuvel Pharmaceuticals has announced positive topline data from the second phase of its study for the use of SCENESSE for photoprotection in variegate porphyria.
Wilsons points out variegate porphyria impacts around 1 in 200,000 people and there are currently no approved treatments, but results demonstrate positive clinical signs to offer a potential treatment.
SCENESSE already has an approved label indication for the related erythropoietic protoporphyria.
The Overweight rating and target price of $25.46 are retained.
This report was published on March 5, 2024.
Target price is $25.46 Current Price is $13.21 Difference: $12.25
If CUV meets the Wilsons target it will return approximately 93% (excluding dividends, fees and charges).
Current consensus price target is $18.75, suggesting upside of 41.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 7.70 cents and EPS of 64.40 cents.
At the last closing share price the estimated dividend yield is 0.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.51.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 69.5, implying annual growth of 12.2%.
Current consensus DPS estimate is 6.3, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 19.0.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 10.40 cents and EPS of 69.10 cents.
At the last closing share price the estimated dividend yield is 0.79%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.12.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 75.6, implying annual growth of 8.8%.
Current consensus DPS estimate is 6.7, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 17.5.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CVN CARNARVON ENERGY LIMITED
Crude Oil – Overnight Price: $0.18
Jarden rates ((CVN)) as Buy (1) –
The first half loss from Carnarvon Energy is "largely irrelevant", Jarden asserts, from a valuation point of view, rather the important aspect is the company expects the interest earned on its cash balance to cover corporate and administrative costs.
There was no new information on the proposal to consider putting the business up for sale. Both the company and the operator of Dorado, Santos ((STO)), have reiterated plans to progress the phase1 liquids development and be FID ready by the end of 2024.
Buy rating and $0.25 target maintained.
This report was published on February 28, 2024.
Target price is $0.25 Current Price is $0.18 Difference: $0.065
If CVN meets the Jarden target it will return approximately 35% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
DGL DGL GROUP LIMITED
Commercial Services & Supplies – Overnight Price: $0.60
Canaccord Genuity rates ((DGL)) as Downgrade to Hold from Speculative Buy (3) –
Canaccord Genuity materially lowers its target for DGL Group to 60c from $1.70 and downgrades its rating to Hold from Speculative Buy after 1H results fell well short of expectations.
Apart from lower earnings forecasts, the analyst's valuation multiple is reduced given volatility for the overall business.
The broker is disappointed by management's FY24 guidance for a year-on-year earnings decline; last year's AGM in November mentioned earnings growth.
Revenue for the half was -25% down on the consensus forecast, while underlying earnings (EBITDA) of $30.3m compared to the forecast for $33m.
All segments, apart from Logistics, missed forecasts, notes the broker. Demand for crop protection products were negatively impacted by forecast drought, which has not materialised.
Management sees a positive demand outlook for chemicals, while warehousing demand is robust and fleet utilisation remains strong.
This report was published on February 29, 2024.
Target price is $0.60 Current Price is $0.60 Difference: minus $0.005 (current price is over target).
If DGL meets the Canaccord Genuity target it will return approximately minus 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $0.76, suggesting upside of 25.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 5.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.43.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.2, implying annual growth of -8.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 9.8.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 7.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.0, implying annual growth of 12.9%.
Current consensus DPS estimate is 0.7, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 8.6.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
DSE DROPSUITE LIMITED
Cloud services – Overnight Price: $0.30
Petra Capital rates ((DSE)) as Buy (1) –
Dropsuite posted 2023 results that were in line with guidance, with revenue growth the key driver.
While Petra Capital reduces operating earnings (EBITDA) estimates for 2024 and 2025 by -44% and -25%, respectively, forecast EPS revisions are less material given the utilisation of tax credits is now assumed to continue into 2027.
Acknowledging the company's ability to leverage a strong balance sheet to supplement what is expected to be multi-year organic growth along with M&A, Petra Capital reiterates a Buy rating and $0.32 target.
This report was published on February 29, 2024.
Target price is $0.32 Current Price is $0.30 Difference: $0.02
If DSE meets the Petra Capital target it will return approximately 7% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 100.00.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 100.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
DSK DUSK GROUP LIMITED
Household & Personal Products – Overnight Price: $0.76
Canaccord Genuity rates ((DSK)) as Downgrade to Hold from Buy (3) –
Solid performance from Dusk Group's first half says Canaccord Genuity, despite the impact of more cautious customer spending on the period.
The broker notes difficult trading conditions have persisted into the second half, but does expect the retailer to benefit from easier comps.
The broker particularly likes that Dusk Group has maintained relatively tight control over gross margins and per store cost of doing business.
The rating is downgraded to Hold from Buy, pending improved sales and earnings execution, and the target price decreases to 90 cents from $1.40.
This report was published on March 4, 2024.
Target price is $0.90 Current Price is $0.76 Difference: $0.14
If DSK meets the Canaccord Genuity target it will return approximately 18% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 6.00 cents and EPS of 7.00 cents.
At the last closing share price the estimated dividend yield is 7.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.86.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 8.00 cents and EPS of 12.00 cents.
At the last closing share price the estimated dividend yield is 10.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.33.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
DUG DUG TECHNOLOGY LIMITED
Cloud services – Overnight Price: $2.40
Canaccord Genuity rates ((DUG)) as Buy (1) –
Following DUG Technology's 1H results, Canaccord Genuity raises its target to $2.90 from $2.00 on increased forecasts and a higher assumed valuation multiple. The Buy rating is maintained.
After the broker strips out -US$2.3m of third part compute costs, 2Q annualised earnings (EBITDA) would be tracking well above $20m
whilst the EBITDA margin would have been in the low 30’s, in-line with recent trends.
The company has effectively doubled its compute through completed and proposed compute purchases, explains the analyst.
The broker's FY25 Services revenue forecast is now roughly equivalent to the level of Services work won over 2023. The current pacing of Services awards is enough to cover Canaccord's FY25 revenue forecast.
This report was published on March 5, 2024.
Target price is $2.90 Current Price is $2.40 Difference: $0.5
If DUG meets the Canaccord Genuity target it will return approximately 21% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 5.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 48.00.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 9.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 26.67.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EOS ELECTRO OPTIC SYSTEMS HOLDINGS LIMITED
Hardware & Equipment – Overnight Price: $1.76
Petra Capital rates ((EOS)) as Hold (3) –
Electro Optic Systems delivered a 2023 net loss of -$34.1m, which was in line with Petra Capital's forecasts and posted record revenue, with both segments of the business making a positive contribution.
The broker observes sufficient cash exists to theoretically cover principal debt obligations and so the company has commenced 2024 in relatively good shape while market conditions are favourable.
Significant progress has been made in delivering on strategic imperatives and the foundations are now in place to generate a profit through increased scale, the broker adds. Hold reiterated. Target is raised to $1.14 from $1.03.
This report was published on February 29, 2024.
Target price is $1.14 Current Price is $1.76 Difference: minus $0.62 (current price is over target).
If EOS meets the Petra Capital target it will return approximately minus 35% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company's fiscal year ends in December.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 9.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 19.13.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of 3.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 55.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EVO EMBARK EARLY EDUCATION LIMITED
Education & Tuition – Overnight Price: $0.58
Petra Capital rates ((EVO)) as Buy (1) –
Petra Capital upgrades forecasts substantially after the 2023 results, which were were ahead of forecasts. Embark Early Education has announced the acquisition of nine highly-accretive childcare centres.
These acquisitions, five in Victoria and four in Queensland, are expected to settle mid-March through to late April and all have high occupancy rates. The price is $25.2m.
As the stock is trading at a significant discount to peers and there is a $20m debt facility for further acquisitions, the broker finds the stock attractive and retains a Buy rating, raising the target 10% to $1.15.
This report was published on February 29, 2024.
Target price is $1.15 Current Price is $0.58 Difference: $0.565
If EVO meets the Petra Capital target it will return approximately 97% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 4.50 cents and EPS of 7.30 cents.
At the last closing share price the estimated dividend yield is 7.69%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.01.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 5.50 cents and EPS of 8.30 cents.
At the last closing share price the estimated dividend yield is 9.40%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.05.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FFM FIREFLY METALS LIMITED
Gold & Silver – Overnight Price: $0.53
Canaccord Genuity rates ((FFM)) as Speculative Buy (1) –
FireFly Metals has released first drill results from its Ming mine footwall zone, in a continuation of high grade results from the Green Bay gold-copper project.
First phase drilling is now 48% complete, says Canaccord Genuity, and the new underground exploration platforms are allowing for quicker and more cost effective drilling. Phase two is expected to commence from mid-year.
The Speculative Buy rating and target price of $1.35 are retained.
This report was published on March 4, 2024.
Target price is $1.35 Current Price is $0.53 Difference: $0.82
If FFM meets the Canaccord Genuity target it will return approximately 155% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FLT FLIGHT CENTRE TRAVEL GROUP LIMITED
Travel, Leisure & Tourism – Overnight Price: $21.51
Goldman Sachs rates ((FLT)) as Neutral (3) –
Flight Centre Travel's 1H results revealed revenue in line with Goldman Sachs forecast, and misses for total transaction value (TTV) and earnings of -4% and -7%, respectively. Softer Corporate earnings weighed though Other provide an offset, explain the analysts.
A summary of the broker's investment thesis is an expected overall recovery led by the Corporate segment while the recovery in Leisure will be below pre-pandemic levels.
The target falls to $20.10 from $20.70 as increases in forecasts for Leisure are offset by falling estimates for Corporate.The Neutral rating is maintained.
This report was published on February 29, 2024.
Target price is $20.10 Current Price is $21.51 Difference: minus $1.41 (current price is over target).
If FLT meets the Goldman Sachs target it will return approximately minus 7% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $24.51, suggesting upside of 14.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 19.00 cents and EPS of 85.00 cents.
At the last closing share price the estimated dividend yield is 0.88%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.31.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 95.7, implying annual growth of 313.7%.
Current consensus DPS estimate is 27.2, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 22.5.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 31.00 cents and EPS of 119.00 cents.
At the last closing share price the estimated dividend yield is 1.44%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 135.4, implying annual growth of 41.5%.
Current consensus DPS estimate is 42.5, implying a prospective dividend yield of 2.0%.
Current consensus EPS estimate suggests the PER is 15.9.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((FLT)) as Upgrade to Buy from Overweight (1) –
First half results missed expectations yet Jarden assesses this was overshadowed by market share gains, with FY24 guidance being reiterated along with a FY25 pre-tax profit aspirational margin of 2%.
The broker updates forecasts to allow for disclosure changes, with the net impact being a 5-6% increase in net profit estimates out to FY27.
The business is larger and leaner, with higher returns on investments compared with pre-pandemic levels and Jarden believes this warrants a premium relative to the 16x FY25 EPS currently implied.
Rating is upgraded to Buy from Overweight and the target lifted to $23.50 from $22.00.
This report was published on February 28, 2024.
Target price is $23.50 Current Price is $21.51 Difference: $1.99
If FLT meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $24.51, suggesting upside of 14.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 55.00 cents and EPS of 87.70 cents.
At the last closing share price the estimated dividend yield is 2.56%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 24.53.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 95.7, implying annual growth of 313.7%.
Current consensus DPS estimate is 27.2, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 22.5.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 91.00 cents and EPS of 138.30 cents.
At the last closing share price the estimated dividend yield is 4.23%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.55.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 135.4, implying annual growth of 41.5%.
Current consensus DPS estimate is 42.5, implying a prospective dividend yield of 2.0%.
Current consensus EPS estimate suggests the PER is 15.9.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GDG GENERATION DEVELOPMENT GROUP LIMITED
Wealth Management & Investments – Overnight Price: $1.95
Moelis rates ((GDG)) as Buy (1) –
Generation Development's first half result was broadly in line, but also compositionally better, than Moelis had anticipated. The company reported net profits of $4.9m, up 67% year-on-year.
Lonsec performed better than expected, reporting net profits of $3.2m compared to the broker's forecast $2.4m, helping to offset a weaker result from the investment bonds segment.
Formal guidance was not provided, but the broker found outlook commentary to be generally positive. The Buy rating is retained and the target price increases to $2.34 from $1.97.
This report was published on February 29, 2024.
Target price is $2.34 Current Price is $1.95 Difference: $0.39
If GDG meets the Moelis target it will return approximately 20% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Moelis forecasts a full year FY24 dividend of 2.20 cents and EPS of 5.70 cents.
At the last closing share price the estimated dividend yield is 1.13%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 34.21.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 2.90 cents and EPS of 7.10 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 27.46.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Petra Capital rates ((GDG)) as Buy (1) –
Petra Capital found the first half result from Generation Development positive, noting a strong contribution from Lonsec.
As the recent strong equity market only contributed two months to the period, the broker assumes some performance benefits will carry into the second half.
The company expects investment bonds to match or exceed the annual sales record from FY22. Buy rating retained. Target rises to $2.40 from $2.18.
This report was published on March 1, 2024.
Target price is $2.40 Current Price is $1.95 Difference: $0.45
If GDG meets the Petra Capital target it will return approximately 23% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 2.40 cents and EPS of 6.40 cents.
At the last closing share price the estimated dividend yield is 1.23%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.47.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 2.60 cents and EPS of 9.60 cents.
At the last closing share price the estimated dividend yield is 1.33%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.31.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GEM G8 EDUCATION LIMITED
Childcare – Overnight Price: $1.22
Canaccord Genuity rates ((GEM)) as Buy (1) –
While G8 Education's FY23 result was generally in line with Canaccord Genuity's expectations, the cash performance was a beat, and the demand outlook has improved, in the broker's view.
Over the period, revenue growth outpaced cost growth, with sales increasing by 9% while wages were managed and agency usage was reduced, explain the analysts.
Early signs are positive for FY24, suggests the broker, with year-to-date occupancy rising by 1.2%, and appearing to outperform against the broader industry.
The target rises to $1.43 from $1.40 and the Buy rating is unchanged.
This report was published on February 29, 2024.
Target price is $1.43 Current Price is $1.22 Difference: $0.21
If GEM meets the Canaccord Genuity target it will return approximately 17% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 5.00 cents and EPS of 9.00 cents.
At the last closing share price the estimated dividend yield is 4.10%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.56.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 5.00 cents and EPS of 9.60 cents.
At the last closing share price the estimated dividend yield is 4.10%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.71.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GNC GRAINCORP LIMITED
Agriculture – Overnight Price: $7.91
Wilsons rates ((GNC)) as Market Weight (3) –
East coast crop volume estimates have been upgraded by the Agricultural Bureau, but this update does diminish the extent of market share improvement implied by GrainCorp's latest guidance.
The Bureau is now anticipating a winter crop of 23.3m tonnes, up 7% on previous expectations and 7% above the ten-year average.
The Market Weight rating is retained and the target price increases to $7.28 from $6.74.
This report was published on March 6, 2024.
Target price is $7.28 Current Price is $7.91 Difference: minus $0.63 (current price is over target).
If GNC meets the Wilsons target it will return approximately minus 8% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $8.66, suggesting upside of 9.5%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 30.00 cents and EPS of 41.60 cents.
At the last closing share price the estimated dividend yield is 3.79%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.01.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 37.5, implying annual growth of -66.4%.
Current consensus DPS estimate is 22.8, implying a prospective dividend yield of 2.9%.
Current consensus EPS estimate suggests the PER is 21.1.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 28.00 cents and EPS of 38.50 cents.
At the last closing share price the estimated dividend yield is 3.54%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.55.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 42.9, implying annual growth of 14.4%.
Current consensus DPS estimate is 25.9, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 18.4.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GNX GENEX POWER LIMITED
EV, Solar & Batteries – Overnight Price: $0.25
Canaccord Genuity rates ((GNX)) as Speculative Buy (1) –
Genex Power has received a non-binding, indicative and conditional proposal from J-POWER for a full take-over by way of a scheme of arrangement for 27.5cps.
The Proposal also contains an alternative structure, under which J-POWER will potentially also, concurrently with the Potential Scheme, make an off-market takeover bid for Genex Shares for 27cps subject to a 50.1% minimum acceptance.
Canaccord Genuity explains the dual structure is likely designed to try and accommodate major holder SKIP, which previously made a bid for Genex at 25cps in conjunction with Stonepeak.
The board of Genex Power has indicated that should a binding bid eventuate, it would recommend the transaction to shareholders in the absence of a superior proposal.
Speculative Buy. Target 26c.
This report was published on February 5, 2024.
Target price is $0.26 Current Price is $0.25 Difference: $0.01
If GNX meets the Canaccord Genuity target it will return approximately 4% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HVN HARVEY NORMAN HOLDINGS LIMITED
Consumer Electronics – Overnight Price: $4.76
Goldman Sachs rates ((HVN)) as Neutral (3) –
First half results from Harvey Norman were slightly weaker than Goldman Sachs expected. Management has signalled a stable operating environment has developed in the second half and expects the first half of FY25 should benefit from rate cuts.
On the international scene, Goldman Sachs notes New Zealand remains challenged although the roll-out in Malaysia has been confirmed.
Store growth in Malaysia is expected to be around seven for FY24, and while less than guided previously, the delay is attributed to timing with management reiterating a commitment to 80 stores by FY28. Neutral retained. Target is $4.30.
This report was published on February 29, 2024.
Target price is $4.30 Current Price is $4.76 Difference: minus $0.46 (current price is over target).
If HVN meets the Goldman Sachs target it will return approximately minus 10% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.72, suggesting downside of -0.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 23.00 cents and EPS of 27.00 cents.
At the last closing share price the estimated dividend yield is 4.83%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.63.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 29.7, implying annual growth of -31.4%.
Current consensus DPS estimate is 21.2, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.0.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 25.00 cents and EPS of 30.00 cents.
At the last closing share price the estimated dividend yield is 5.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.87.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 35.0, implying annual growth of 17.8%.
Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 5.3%.
Current consensus EPS estimate suggests the PER is 13.6.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((HVN)) as Neutral (3) –
Harvey Norman's first half was 17% ahead of Jarden's estimate as like-for-like trends improved through December, and Dec Q profit fell -10% versus -49% in the June Q.
These trends have continued into January, when sales turned positive in six out of seven regions and inventory was clean.
Jarden believes the market continues to underestimate the international opportunity, with management reiterating its target for 80 stores in Malaysia by FY28 and formally announcing its entrance into England.
The key question for Jarden is why Harvey Norman has not initiated a buyback given the strength of cash flow, lifted the payout ratio or undertaken a special dividend given the franking balance.
The broker retains Neutral but with a positive bias, given positive earnings momentum, tailwinds from the replacement cycle and potential catalysts from a capital return. Target rises to $4.80 from $3.60.
This report was published on March 8, 2024.
Target price is $4.80 Current Price is $4.76 Difference: $0.04
If HVN meets the Jarden target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $4.72, suggesting downside of -0.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 25.00 cents and EPS of 31.80 cents.
At the last closing share price the estimated dividend yield is 5.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.97.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 29.7, implying annual growth of -31.4%.
Current consensus DPS estimate is 21.2, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.0.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 27.00 cents and EPS of 37.10 cents.
At the last closing share price the estimated dividend yield is 5.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.83.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 35.0, implying annual growth of 17.8%.
Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 5.3%.
Current consensus EPS estimate suggests the PER is 13.6.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IPD IMPEDIMED LIMITED
Medical Equipment & Devices – Overnight Price: $0.12
Canaccord Genuity rates ((IPD)) as Buy (1) –
ImpediMed's 1H results were in line with the 2Q trading update. As Canaccord Genuity expected, revenue growth was weak and the broker suggests the recent fall in share price is overdone as progress adding payors and critical mass states has been solid.
The analyst believes Sozo's launch trajectory should be viewed positively as a land grab with new management taking a structured approach to focusing on the growth opportunity.
Canaccord's target falls to 14c from 18c due to the impact of a slower-than-expected sales cycle. The Buy rating is unchanged.
This report was published on February 29, 2024.
Target price is $0.14 Current Price is $0.12 Difference: $0.025
If IPD meets the Canaccord Genuity target it will return approximately 22% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 1.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 8.85.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 1.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 10.45.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Taylor Collison rates ((IPD)) as Hold (3) –
Taylor Collison has been left underwhelmed by ImpediMed's first half result, with the company reporting organic sales growth of just 3%.
The broker still considers conditions buoyant, pointing to a potential multi-year supply pipeline in the infrastructure and data centre segments.
As per Taylor Collison, the set up for ImpediMed's FY24 and FY25 is really about the CMI acquisition, and particulalry the durability of earnings.
The broker moves to a Hold recommendation and the target price decreases to $5.00 from $5.40.
This report was published on February 27, 2024.
Target price is $5.00 Current Price is $0.12 Difference: $4.885
If IPD meets the Taylor Collison target it will return approximately 4248% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Taylor Collison forecasts a full year FY24 dividend of 5.90 cents and EPS of 25.00 cents.
At the last closing share price the estimated dividend yield is 51.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 0.46.
Forecast for FY25:
Taylor Collison forecasts a full year FY25 dividend of 6.00 cents and EPS of 29.80 cents.
At the last closing share price the estimated dividend yield is 52.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 0.39.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IR1 IRIS METALS LIMITED
Overnight Price: $0.48
Petra Capital rates ((IR1)) as Buy (1) –
Iris Metals released drilling results from its Beecher spodumene project in South Dakota. Petra Capital found the results impressive yet notes the stock sold off materially on the news because execution of the diamond drill program has been delayed.
Project fundamentals have not changed, yet the broker reduces the target to $1.67 from $2.57 because of lower peer multiples and additional dilution from a lower share price.
The timeline for catalysts has also been pushed out. A Buy rating is maintained on valuation grounds.
This report was published on February 29, 2024.
Target price is $1.67 Current Price is $0.48 Difference: $1.19
If IR1 meets the Petra Capital target it will return approximately 248% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JLG JOHNS LYNG GROUP LIMITED
Building Products & Services – Overnight Price: $6.58
Canaccord Genuity rates ((JLG)) as Buy (1) –
Johns Lyng's 1H underlying earnings of $69.7m compared to forecasts by Canaccord Genuity and consensus for $68.6m and $65m, respectively.
A material share price fall in reaction to the result was overdone, in the broker's view.
While the market appeared to be disappointed by the financial performance of the US operations, the analyst points out the US move is at a relatively early stage, with significant progress made so far.
Management increased FY24 guidance for underlying EBITDA to $136.4m from $128m on a 3.5% increase in revenues, with CAT work the key driver, explains Canaccord.
The broker retains a Buy rating and the target falls to $8.65 from $9.00.
This report was published on February 29, 2024.
Target price is $8.65 Current Price is $6.58 Difference: $2.07
If JLG meets the Canaccord Genuity target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $7.31, suggesting upside of 11.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 11.00 cents and EPS of 21.50 cents.
At the last closing share price the estimated dividend yield is 1.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.60.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.2, implying annual growth of 12.6%.
Current consensus DPS estimate is 9.7, implying a prospective dividend yield of 1.5%.
Current consensus EPS estimate suggests the PER is 32.6.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 11.80 cents and EPS of 23.80 cents.
At the last closing share price the estimated dividend yield is 1.79%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 27.65.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.5, implying annual growth of 11.4%.
Current consensus DPS estimate is 10.6, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 29.2.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
KAR KAROON ENERGY LIMITED
Crude Oil – Overnight Price: $1.91
Goldman Sachs rates ((KAR)) as Buy (1) –
Karoon Energy's half-year results were below Goldman Sachs estimates. While the company is moving to a December year end, the broker retains a June year end in its modelling.
Management plans to complete a strategy review by the end of the year, which the broker expects will assess the balance between acquisitions, exploration and organic growth. Shareholder returns are expected to benefit from the free cash flow generated over 2024.
Buy rating and $2.38 target.
This report was published on February 29, 2024.
Target price is $2.38 Current Price is $1.91 Difference: $0.475
If KAR meets the Goldman Sachs target it will return approximately 25% (excluding dividends, fees and charges).
Current consensus price target is $2.76, suggesting upside of 44.8%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 0.00 cents and EPS of 54.69 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 3.48.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 49.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 3.8.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 0.00 cents and EPS of 45.57 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 42.4, implying annual growth of -14.9%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 4.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((KAR)) as Buy (1) –
A surprise tax break was a key highlight for Jarden in Karoon Energy's result. Progress on new well connections and appraisal drilling is a little slower than expected, but with no impact to 2024 production guidance.
All other 2024 guidance is unchanged, though unapproved Who Dat drilling could add extra cost, the broker warns.
Key near-term catalysts include a decision on whether to progress Neon to the next evaluation phase, appraisal drilling at Who Dat East and exploration drilling in 2H24.
Buy and $2.40 target retained, with higher transport costs offsetting lower tax payments.
This report was published on March 8, 2024.
Target price is $2.40 Current Price is $1.91 Difference: $0.495
If KAR meets the Jarden target it will return approximately 26% (excluding dividends, fees and charges).
Current consensus price target is $2.76, suggesting upside of 44.8%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 25.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.62.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 49.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 3.8.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 26.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 42.4, implying annual growth of -14.9%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 4.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
KED KEYPATH EDUCATION INTERNATIONAL INC
Education & Tuition – Overnight Price: $0.57
Canaccord Genuity rates ((KED)) as Buy (1) –
Keypath Education International’s result contained few surprises, having largely been pre-released. Positive adjusted earnings were the main positive takeaway, Canaccord Genuity suggests, noting a strong level of incremental contribution margin drop-through.
Underlying unit economics appear to be strengthening, the broker notes, with student vintages achieving greater contribution margins sooner, which indicates that management has found solid product-market fit.
Canaccord believes there is ample look-through to future revenue growth in the mid-teens, given the high degree of visibility in the pipelines/vintages.
Target rises to $1.10 from 96c, Buy retained.
This report was published on March 8, 2024.
Target price is $1.10 Current Price is $0.57 Difference: $0.53
If KED meets the Canaccord Genuity target it will return approximately 93% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
KYP KINATICO LIMITED
Software & Services – Overnight Price: $0.10
Taylor Collison rates ((KYP)) as Outperform (2) –
Taylor Collison was left unsurprised by Kinatico's first half results, as the company reported growth in software as a service revenue to $4.4m, up 159% year-on-year, and improved net profits of $0.4m.
The broker was left pleased with persistant gross profit margin expansion, lifting to 67.7% from 66.9% half-on-half. Taylor Collison points out this benefit continues to emerge as the company moves away from lower margin credential checks, and believes there is further upside.
The Outperform rating is retained with no target price provided.
This report was published on February 26, 2024.
Current Price is $0.10. Target price not assessed.
The company's fiscal year ends in June.
Forecast for FY24:
Taylor Collison forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 52.50.
Forecast for FY25:
Taylor Collison forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.00.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
LBL LASERBOND LIMITED
Mining Sector Contracting – Overnight Price: $0.69
Canaccord Genuity rates ((LBL)) as Buy (1) –
Despite softer-than-expected revenue and earnings in the 1H due to a shortage of raw material, Canaccord Genuity is more focused on the opportunity afforded by the announced expansion into Western Australia. It's also felt the first half misses can be largely recovered.
The company is acquiring a 40% stake in the Gateway Group. Gateway supplies machinery parts to customers and also offers chrome plating, which looks to be a neat fit with Laserbond's laser cladding capabilities, in the broker's opinion.
The target rises to $1.25 from $1.15 after the analyst lowers the FY24 earnings forecast but raises estimates for FY25 and FY26. The Buy rating for Laserbond is maintained.
This report was published on February 29, 2024.
Target price is $1.25 Current Price is $0.69 Difference: $0.56
If LBL meets the Canaccord Genuity target it will return approximately 81% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 1.70 cents and EPS of 4.90 cents.
At the last closing share price the estimated dividend yield is 2.46%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.08.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 1.90 cents and EPS of 8.70 cents.
At the last closing share price the estimated dividend yield is 2.75%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.93.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
LNW LIGHT & WONDER INC
Gaming – Overnight Price: $151.92
Jarden rates ((LNW)) as Downgrade to Overweight from Buy (2) –
Light & Wonder provided a strong quarterly outcome with above-industry earnings growth in 2023 of 22%. Jarden believes revenue growth across all the three businesses should lead to the market upgrading estimates and closing the gap on what is achievable.
The broker considers the company a more focused business that continues to grow share via a diversified and incentivised world-class game design team.
Overweight rating, downgraded from Buy following recent outperformance in the share price. Target is raised to $161 from $147.
This report was published on February 29, 2024.
Target price is $161.00 Current Price is $151.92 Difference: $9.08
If LNW meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 419.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 36.26.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 542.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 28.02.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
M7T MACH7 TECHNOLOGIES LIMITED
Healthcare services – Overnight Price: $0.70
Wilsons rates ((M7T)) as Overweight (1) –
Mach7 Technologies largely pre-released its first half results and has maintained downgraded FY24 revenue guidance of $27-30m. Despite the loss of upfront revenue, management's target for cash flow breakeven in FY24 has been retained.
Wilsons expects the share price will be driven by new contracts gained over the remainder of FY24. The following year should represent a step change, as the number of wins in the preceding 12-18 months show up in the profit and loss.
Wilsons maintains an Overweight rating and $1.05 target.
This report was published on March 1, 2024.
Target price is $1.05 Current Price is $0.70 Difference: $0.345
If M7T meets the Wilsons target it will return approximately 49% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 3.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 19.05.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 2.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 32.05.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MAQ MACQUARIE TECHNOLOGY GROUP LIMITED
Telecommunication – Overnight Price: $79.61
Canaccord Genuity rates ((MAQ)) as Buy (1) –
Macquarie Technology posted a beat relative to Canaccord Genuity's first-half expectations, FY guidance that points to an upgrade to consensus, robust cash generation and a clear plan for growth. All in all "hugely satisfactory".
Despite significant investment in IC3 East, an asset which is not yet billing at full capacity, the broker highlights the company generates a return on capital above 20% by virtue of its diversified business model across Telecom, Cloud Services & Government and Data Centre services.
Canaccord has lifted earnings forecasts in line with commentary and increased its target to $90.25 from $87.50, Buy retained.
This report was published on March 8, 2024.
Target price is $90.25 Current Price is $79.61 Difference: $10.64
If MAQ meets the Canaccord Genuity target it will return approximately 13% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 131.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 60.77.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 164.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 48.54.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Petra Capital rates ((MAQ)) as Buy (1) –
Petra Capital found the first half result from Macquarie Technology "solid", with much of the focus on planning and approval of Super West. Guidance for FY24 EBITDA is $108-111m, in line with forecasts.
Capital intensity was lower than the broker had expected, on account of the completion of the Telecom refresh project and delays to the commencement of Super West.
Estimates for FY24 and FY25 are upgraded and the broker moves to a market multiple valuation approach. Buy retained. Target rises to $89.77 from $79.64.
This report was published on March 1, 2024.
Target price is $89.77 Current Price is $79.61 Difference: $10.16
If MAQ meets the Petra Capital target it will return approximately 13% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of 130.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 61.10.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of 158.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 50.29.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MDR MEDADVISOR LIMITED
Healthcare services – Overnight Price: $0.29
Canaccord Genuity rates ((MDR)) as Buy (1) –
MedAdvisor released a result in line with Canaccord Genuity, and with additional disclosure around customer mix, investment in the tech offering, and a pathway to operating leverage.
The company is executing well on its strategy to focus on the higher value pharma offerings in the US market, the broker suggests, including vaccines and an omni-channel approach, with AI tools under development.
Targeted and direct-to-patient pharma marketing represents a real and growing opportunity, in Canaccord's view. A clear and structured path forward could illuminate a material, scalable growth story.
The broker concludes the company is executing well on its long-term ambitions, with a pathway for scale at the top and bottom lines.
Buy and 39c target retained.
This report was published on March 8, 2024.
Target price is $0.39 Current Price is $0.29 Difference: $0.095
If MDR meets the Canaccord Genuity target it will return approximately 32% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.75.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 29.50.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Moelis rates ((MDR)) as Buy (1) –
Moelis has described the strong first half result from MedAdvisor "as expected", with revenue and gross profit pre-announced in January. The company grew revenue 18% year-on-year to $75.5m, gross profit 13% to $43.5m and net profit to $6.9m.
As per Moelis, MedAdvisor continues to gain momentum in the US as it further diversifies across new diseases, vaccines and customers, onboarding eleven new brands in the half.
The company is also looking to invest -$10-15m in technology through to FY26, driving both development and improved efficiencies.
The Buy rating is retained and the target price increases to 38 cents from 36 cents.
This report was published on February 29, 2024.
Target price is $0.38 Current Price is $0.29 Difference: $0.085
If MDR meets the Moelis target it will return approximately 29% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Moelis forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 73.75.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MEI METEORIC RESOURCES NL
Gold & Silver – Overnight Price: $0.21
Canaccord Genuity rates ((MEI)) as Speculative Buy (1) –
Meteoric Resources has reported more positive metallurgical test work results from Caldeira, as well as the production of first mixed rare earth carbonate from test ores.
Contained grades and low impurities could support improved product payabilities, Canaccord Genuity suggests, with ongoing test work expected to provide samples for offtake discussions.
Meteoric has several upcoming potential catalysts, the broker notes, including further met test work results, resource upgrade optimisation and initial scoping studies.
Speculative Buy and 45c target retained.
This report was published on March 8, 2024.
Target price is $0.45 Current Price is $0.21 Difference: $0.24
If MEI meets the Canaccord Genuity target it will return approximately 114% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Petra Capital rates ((MEI)) as Buy (1) –
Meteoric Resources has produced a sample of mixed rare-earth carbonate using ore from Caldeira. Petra Capital notes recoveries achieved were materially higher than in previous test work and imply 8% increase in recovered product per tonne of feed.
This in turn has positive economic implications for the upcoming maiden mining study. The broker believes Caldeira is the best undeveloped ionic rare earth project globally and reiterates a Buy rating with a $0.42 target.
This report was published on March 1, 2024.
Target price is $0.42 Current Price is $0.21 Difference: $0.21
If MEI meets the Petra Capital target it will return approximately 100% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 52.50.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 0.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 35.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MOZ MOSAIC BRANDS LIMITED
Apparel & Footwear – Overnight Price: $0.14
Wilsons rates ((MOZ)) as Market Weight (3) –
Mosaic Brands posted earnings in the first half that were ahead of estimates and Wilsons believes the business is well-placed to improve like-for-like sales growth as stock is refreshed and underperforming stores close.
No quantitative guidance was provided. The company announced the retirement of current CEO, Scott Evans, appointing Erica Berchtold in his place. Wilsons retains a Market Weight rating, given recent earnings volatility. Target is reduced to $0.16 from $0.18.
This report was published on March 1, 2024.
Target price is $0.16 Current Price is $0.14 Difference: $0.025
If MOZ meets the Wilsons target it will return approximately 19% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 4.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 2.87.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 9.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 1.41.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MXI MAXIPARTS LIMITED
Automobiles & Components – Overnight Price: $2.20
Taylor Collison rates ((MXI)) as Outperform (2) –
MaxiPARTS has confirmed positive industry conditions are being experienced in the second half and Taylor Collision believes this could be the beginning of a multi-year earnings and margin growth story.
The broker finds the multiples undemanding and while the first half was considered "messy", the true run rate of the business should become visible in the second half and provide a catalyst for re-rating. Outperform and $2.95 target.
This report was published on February 23, 2024.
Target price is $2.95 Current Price is $2.20 Difference: $0.75
If MXI meets the Taylor Collison target it will return approximately 34% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Taylor Collison forecasts a full year FY24 dividend of 6.60 cents and EPS of 16.40 cents.
At the last closing share price the estimated dividend yield is 3.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.41.
Forecast for FY25:
Taylor Collison forecasts a full year FY25 dividend of 8.40 cents and EPS of 21.10 cents.
At the last closing share price the estimated dividend yield is 3.82%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.43.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NEU NEUREN PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $20.07
Canaccord Genuity rates ((NEU)) as Buy (1) –
Neuren Pharmaceuticals reported its 2023 result a day after its US distribution partner Acadia's reported. The market reacted negatively to detailed 2024 Daybue sales guidance, Canaccord Genuity notes.
2024 guided sales are in line with the broker, but seasonality-driven softness anticipated in the first quarter drew negative attention.
Persistence and longer-term compliance with therapy remain the key unknowns going forward, but real-world patient experience was reported positively, Canaccord notes, outperforming clinical trial metrics.
The broker suggests Neuren is still offering healthy upside potential above new lows. Buy and $31 target retained.
This report was published on March 8, 2024.
Target price is $31.00 Current Price is $20.07 Difference: $10.93
If NEU meets the Canaccord Genuity target it will return approximately 54% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 54.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 37.17.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 90.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 22.30.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Wilsons rates ((NEU)) as Overweight (1) –
Neuren Pharmaceuticals delivered operating earnings (EBITDA) in 2023 of $199.5m, ahead of forecasts. Net profit was also ahead of expectations, reflecting a maiden year of commercial revenue from Daybue.
Wilsons lauds the cash balance which will fund the R&D pipeline and believes the stock still represents a rare opportunity, retaining an Overweight rating and $26.58 target.
This report was published on March 1, 2024.
Target price is $26.58 Current Price is $20.07 Difference: $6.51
If NEU meets the Wilsons target it will return approximately 32% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 50.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.66.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 32.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 62.52.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NXD NEXTED GROUP LIMITED
Education & Tuition – Overnight Price: $0.39
Canaccord Genuity rates ((NXD)) as Buy (1) –
Canaccord Genuity slashes its target for NextEd Group to 70c from $1.20 following 1H results after management withdrew 2H guidance due to recent legislative changes and particularly volatile visa approval data. The 1H result was largely pre-released.
By way of example, the analyst notes universities have gone so far as to withdraw students Confirmation of Enrolment ahead of a decision on their visa on the basis a student may be “unlikely to meet new criteria to obtain a positive visa outcome”.
The broker retains a Buy rating and notes management is pointing to improvements in FY25 and FY26 for yield and profitability.
Relative to FY23, the company is guiding to a 200bps lift for pre-and post-AASB16 FY26 EBITDA margins, and a 200bps improvement for the FY26 NPATA margin.
A cost-out plan of -$2.5m was also announced along with consolidation of some leased classroom infrastructure.
This report was published on February 29, 2024.
Target price is $0.70 Current Price is $0.39 Difference: $0.315
If NXD meets the Canaccord Genuity target it will return approximately 82% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 38.50.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NXS NEXT SCIENCE LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.36
Canaccord Genuity rates ((NXS)) as Speculative Buy (1) –
Next Science's FY23 revenue was in line with management guidance, with direct product sales of US$16.9m highlighting success via the durable medical equipment (DME platform), with some contribution from Xperience. Management maintained FY24 guidance.
The earnings (EBITDA) loss of -US$14.8m reflects ongoing investment into sales and marketing to support the DME segment, explains the broker.
Cash at December 31 was $9.2m. The analyst notes the balance sheet remains under pressure (despite a recent capital injection) though believes management is taking the right measures for the near-term by controlling costs.
The Speculative Buy rating and 40c target are unchanged.
This report was published on March 5, 2024.
Target price is $0.40 Current Price is $0.36 Difference: $0.035
If NXS meets the Canaccord Genuity target it will return approximately 10% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NXT NEXTDC LIMITED
Cloud services – Overnight Price: $17.39
Canaccord Genuity rates ((NXT)) as Buy (1) –
Canaccord Genuity assesses a "solid" 1H for NextDC with revenue a 6% beat versus the broker's forecast.
As capex was around -$150m lower than expectations for the half, net debt was similarly below expectations held by consensus and the analysts.
The broker points out 23MW of the 27MW added in the 1H was announced last August and the balance was sold in the interim.
Management's FY24 guidance is unchanged from the August 2023 update.
Canaccord Genuity retains its $14.65 target and Buy rating.
This report was published on February 29, 2024.
Target price is $14.65 Current Price is $17.39 Difference: minus $2.74 (current price is over target).
If NXT meets the Canaccord Genuity target it will return approximately minus 16% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $18.77, suggesting upside of 7.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 EPS of minus 7.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 228.82.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -9.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 EPS of minus 7.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 225.84.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -17.5, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ORI ORICA LIMITED
Mining Sector Contracting – Overnight Price: $16.89
Jarden rates ((ORI)) as Buy (1) –
With global gold production expected to grow, Jarden sees good sense in further expansion into the North American gold sector for Orica, and considers the intended acquisition of Cyanco a step towards increased geographical diversification.
While synergies appear minimal, Jarden maintains diversification into North America is an important step for Orica. The broker does not anticipate further acquisitions in FY24, but considers Orica's balance sheet well positioned.
The Buy rating and target price of $17.75 are retained.
This report was published on March 4, 2024.
Target price is $17.75 Current Price is $16.89 Difference: $0.86
If ORI meets the Jarden target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $18.19, suggesting upside of 7.7%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 47.50 cents and EPS of 86.10 cents.
At the last closing share price the estimated dividend yield is 2.81%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.62.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 94.0, implying annual growth of 44.4%.
Current consensus DPS estimate is 49.7, implying a prospective dividend yield of 2.9%.
Current consensus EPS estimate suggests the PER is 18.0.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 53.80 cents and EPS of 97.20 cents.
At the last closing share price the estimated dividend yield is 3.19%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.38.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 111.4, implying annual growth of 18.5%.
Current consensus DPS estimate is 58.3, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 15.2.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PPG PRO-PAC PACKAGING LIMITED
Paper & Packaging – Overnight Price: $0.21
Moelis rates ((PPG)) as Buy (1) –
An ongoing consumer slow down did impact on volumes for Pro-Pac Packaging in the first half, concludes Moelis, but the broker still considers the longer term strategy strong.
Pro-Pac Packaging reported a -13% year-on-year decline in flexibles revenue to $124.5m, and a -14% decline in specialty packaging revenue to $34.4m. Earnings were a positive $1.2m as benefits of cost out initiatives flowed through.
The broker anticipates a near break even earnings result over the full year, as conditions remain challenging.
The Buy rating is retained and the target price decreases to 28 cents from 38 cents.
This report was published on March 11, 2024.
Target price is $0.28 Current Price is $0.21 Difference: $0.07
If PPG meets the Moelis target it will return approximately 33% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Moelis forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 7.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 2.96.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 4.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 5.25.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PPM PEPPER MONEY LIMITED
Business & Consumer Credit – Overnight Price: $1.65
Goldman Sachs rates ((PPM)) as Buy (1) –
Pepper Money posted 2023 earnings that were ahead of Goldman Sachs. The interim dividend of five cents was also ahead of expectations.
The company will undertake an on-market buyback of up to 10% of its ordinary shares on issue and has increased the targeted dividend payout ratio to 30-60% of pro forma net profit.
Goldman Sachs observes management has shown an ability to manage its expenses and the buyback and dividend payout target reflect a "rational response" to a more difficult growth environment. Buy rating reiterated. Target rises to $1.62 from $1.45.
This report was published on February 29, 2024.
Target price is $1.62 Current Price is $1.65 Difference: minus $0.025 (current price is over target).
If PPM meets the Goldman Sachs target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company's fiscal year ends in December.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 11.00 cents and EPS of 23.00 cents.
At the last closing share price the estimated dividend yield is 6.69%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.15.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 12.00 cents and EPS of 27.00 cents.
At the last closing share price the estimated dividend yield is 7.29%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.09.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((PPM)) as Overweight (2) –
Pepper Money's earnings were better than Jarden had estimated but the beat was driven partly by provision releases, higher loan sales and strong cost discipline, while margins were weaker. But the worst has likely passed.
The broker does not expect a material earnings recovery until 2025 but the outlook is now brighter, given lower RMBS funding costs and improving new mortgage flows, while the new buyback also provides support.
Jarden continues to see Pepper Money as a proven cyclical business with attractive through-the-cycle appeal.
Overweight retained, target rises to $1.60 from $1.50.
This report was published on March 8, 2024.
Target price is $1.60 Current Price is $1.65 Difference: minus $0.045 (current price is over target).
If PPM meets the Jarden target it will return approximately minus 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company's fiscal year ends in December.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 9.00 cents and EPS of 20.00 cents.
At the last closing share price the estimated dividend yield is 5.47%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.23.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 9.00 cents and EPS of 25.00 cents.
At the last closing share price the estimated dividend yield is 5.47%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.58.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PPT PERPETUAL LIMITED
Wealth Management & Investments – Overnight Price: $24.71
Jarden rates ((PPT)) as Overweight (2) –
Underlying first half results from Perpetual were ahead of Jarden's estimates. Cost synergies from Pendal are on track for a full $80m run rate by January 2025 and the broker envisages scope for cost growth to decelerate sharply.
While more stable and consistent net flows are key to driving improved growth post FY25, the broker considers the current stock multiples provide a potential value catalyst. Overweight retained. Target is reduced to $26.90 from $27.50.
This report was published on February 28, 2024.
Target price is $26.90 Current Price is $24.71 Difference: $2.19
If PPT meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $26.73, suggesting upside of 8.2%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 132.30 cents and EPS of 171.70 cents.
At the last closing share price the estimated dividend yield is 5.35%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.39.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 184.3, implying annual growth of 151.7%.
Current consensus DPS estimate is 130.8, implying a prospective dividend yield of 5.3%.
Current consensus EPS estimate suggests the PER is 13.4.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 146.30 cents and EPS of 189.30 cents.
At the last closing share price the estimated dividend yield is 5.92%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.05.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 208.9, implying annual growth of 13.3%.
Current consensus DPS estimate is 145.0, implying a prospective dividend yield of 5.9%.
Current consensus EPS estimate suggests the PER is 11.8.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PTM PLATINUM ASSET MANAGEMENT LIMITED
Wealth Management & Investments – Overnight Price: $1.15
Goldman Sachs rates ((PTM)) as Sell (5) –
Platinum Asset Management has reported first half results that were largely in line with Goldman Sachs. A turnaround program has been announced which will be delivered in two phases, a "reset phase" and a "growth phase".
The broker finds the plan a positive initiative but awaits any observations around opportunities that have been identified to improve performance, as no targets have been offered.
The broker suspects improving distribution capability and positioning for growth may require investment. Sell rating retained. Target is reduced to $1.00 from $1.12.
This report was published on March 1, 2024.
Target price is $1.00 Current Price is $1.15 Difference: minus $0.15 (current price is over target).
If PTM meets the Goldman Sachs target it will return approximately minus 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $1.14, suggesting downside of -0.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 13.00 cents and EPS of 11.00 cents.
At the last closing share price the estimated dividend yield is 11.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.45.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.6, implying annual growth of -17.7%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 10.4%.
Current consensus EPS estimate suggests the PER is 9.9.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 9.00 cents and EPS of 9.00 cents.
At the last closing share price the estimated dividend yield is 7.83%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.78.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 10.3, implying annual growth of -11.2%.
Current consensus DPS estimate is 9.7, implying a prospective dividend yield of 8.4%.
Current consensus EPS estimate suggests the PER is 11.2.
Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((PTM)) as Underweight (4) –
Platinum Asset Management has proven far less resilient in recent years, Jarden notes, with FY24 earnings on track for an almost -60% decline since FY21.
Pleasingly for the broker, alongside a slight profit beat, the board has approved a new turnaround strategy aimed at resetting the organisation, including its cost base, and repositioning it for growth.
While Jarden supports this initiative, executing will be challenging, and with net benefits unclear and flagship fund investment performance still a headwind for flows, Underweight retained. Target falls to $1.06 from $1.09.
This report was published on March 8, 2024.
Target price is $1.06 Current Price is $1.15 Difference: minus $0.09 (current price is over target).
If PTM meets the Jarden target it will return approximately minus 8% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $1.14, suggesting downside of -0.9%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 10.70 cents and EPS of 11.50 cents.
At the last closing share price the estimated dividend yield is 9.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.6, implying annual growth of -17.7%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 10.4%.
Current consensus EPS estimate suggests the PER is 9.9.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 8.10 cents and EPS of 9.30 cents.
At the last closing share price the estimated dividend yield is 7.04%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.37.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 10.3, implying annual growth of -11.2%.
Current consensus DPS estimate is 9.7, implying a prospective dividend yield of 8.4%.
Current consensus EPS estimate suggests the PER is 11.2.
Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
QOR QORIA LIMITED
Software & Services – Overnight Price: $0.24
Canaccord Genuity rates ((QOR)) as Buy (1) –
Key metrics were released prior to Qoria's 1H result. Cash opex of $44m was 10% higher than the analysts' forecast resulting in adjusted earnings (EBITDA) of -$9.9m.
The broker points out Qoria has switched to capitalizing R&D ($8m in the 1H). Consequently, adjusted earnings (EBITDA) improved to -$1.9m.
Management noted the “seasonally strongest sales period” and reiterated the company will be “OCF positive and profitable on a
monthly Cash EBITDA in 2024”.
The 40c target and Buy rating are unchanged.
This report was published on February 29, 2024.
Target price is $0.40 Current Price is $0.24 Difference: $0.155
If QOR meets the Canaccord Genuity target it will return approximately 63% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 4.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 5.98.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 24.50.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
RED RED 5 LIMITED
Gold & Silver – Overnight Price: $0.34
Moelis rates ((RED)) as Upgrade to Buy from Hold (1) –
Moelis has taken a closer look at the proposed merger of Red 5 and Silver Lake Resources ((SLR)) following the release of half year results from both companies.
While Red 5 will technically take over Silver Lake Resources, the broker points out key executive roles are being favoured towards Silver Lake.
The broker expects the balance sheet impediments causing capital constraints at Red 5's King of the Hills site will be removed within twelve months, and believes Silver Lake Resources may have beat other peers to the punch given the strategic merits the site offers.
The rating is upgraded to Buy and the target price increases to 40 cents from 35 cents.
This report was published on March 3, 2024.
Target price is $0.40 Current Price is $0.34 Difference: $0.055
If RED meets the Moelis target it will return approximately 16% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Moelis forecasts a full year FY24 dividend of 8.00 cents and EPS of 0.80 cents.
At the last closing share price the estimated dividend yield is 23.19%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 43.12.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 9.90 cents and EPS of 1.40 cents.
At the last closing share price the estimated dividend yield is 28.70%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 24.64.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
RHC RAMSAY HEALTH CARE LIMITED
Healthcare services – Overnight Price: $55.15
Jarden rates ((RHC)) as Neutral (3) –
Ramsay Health Care's weak result was largely as Jarden expected. Margin weakness in the Australian business was in line with the broker's estimate.
Despite the weakness in the financials, there appeared to be more promise in the results, the broker suggests, with rhetoric on controlling labour costs, favourable PHI negotiations, a rebound in Elysium, strong momentum in UK hospitals, and the prospect of strategic review of assets to unlock value.
The tone is very encouraging but Jarden needs to see evidence these dynamics are occurring, particularly in light of Ramsay's current valuation. Neutral retained, target rises to $63.43 from $61.26.
This report was published on March 8, 2024.
Target price is $63.43 Current Price is $55.15 Difference: $8.28
If RHC meets the Jarden target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $58.60, suggesting upside of 6.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 82.00 cents and EPS of 145.00 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 38.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 131.0, implying annual growth of 4.7%.
Current consensus DPS estimate is 78.5, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 42.1.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 100.00 cents and EPS of 220.00 cents.
At the last closing share price the estimated dividend yield is 1.81%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.07.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 203.4, implying annual growth of 55.3%.
Current consensus DPS estimate is 124.2, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 27.1.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Wilsons rates ((RHC)) as Market Weight (3) –
First half results were ahead of expectations, Wilsons having feared operating downgrades heading into the result.
Ramsay Health Care's upside now depends on whether the sort of returns on brownfield sites from before the pandemic are still achievable.
The broker concludes in the short term this is likely, at least on the domestic front. Market Weight rating retained. Target rises to $51.61 from $50.00.
This report was published on March 1, 2024.
Target price is $51.61 Current Price is $55.15 Difference: minus $3.54 (current price is over target).
If RHC meets the Wilsons target it will return approximately minus 6% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $58.60, suggesting upside of 6.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 95.40 cents and EPS of 143.80 cents.
At the last closing share price the estimated dividend yield is 1.73%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 38.35.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 131.0, implying annual growth of 4.7%.
Current consensus DPS estimate is 78.5, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 42.1.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 125.00 cents and EPS of 200.40 cents.
At the last closing share price the estimated dividend yield is 2.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 27.52.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 203.4, implying annual growth of 55.3%.
Current consensus DPS estimate is 124.2, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 27.1.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
S32 SOUTH32 LIMITED
Mining – Overnight Price: $2.92
Goldman Sachs rates ((S32)) as Buy (1) –
South32 has agreed to sell the Illawarra metallurgical coal operation for consideration of up to US$1.65bn. This is ahead of Goldman Sachs' asset valuation and implies a potential 6% uplift to its valuation of the stock if the deal is completed.
The company is more than halfway through a 3-4 year investment program at the Appin mine to lengthen the longwall panels and the mine is well capitalised. The broker makes no changes to its Buy rating and $3.80 target.
This report was published on February 29, 2024.
Target price is $3.80 Current Price is $2.92 Difference: $0.88
If S32 meets the Goldman Sachs target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $3.67, suggesting upside of 25.6%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 8.81 cents and EPS of 19.60 cents.
At the last closing share price the estimated dividend yield is 3.02%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.90.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.4, implying annual growth of N/A.
Current consensus DPS estimate is 2.9, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 21.8.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 21.72 cents and EPS of 48.00 cents.
At the last closing share price the estimated dividend yield is 7.44%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 34.3, implying annual growth of 156.0%.
Current consensus DPS estimate is 7.6, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 8.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SDR SITEMINDER LIMITED
Travel, Leisure & Tourism – Overnight Price: $5.56
Jarden rates ((SDR)) as Buy (1) –
In the wake of the first half results from SiteMinder, which were largely pre-announced, Jarden upgrades FY24-26 revenue estimates by 2-3%. The broker envisages multiple levers to grow revenue with further increases in subscription ARPU and property count.
Jarden also upgrades EBITDA for FY24 by 370% and FY25 by 33%, stemming from operational leverage. Buy rating reiterated. Target is raised to $5.48 from $5.00.
This report was published on February 28, 2024.
Target price is $5.48 Current Price is $5.56 Difference: minus $0.08 (current price is over target).
If SDR meets the Jarden target it will return approximately minus 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $6.18, suggesting upside of 11.2%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 9.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 58.53.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -8.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 0.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 695.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -1.7, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SHV SELECT HARVESTS LIMITED
Agriculture – Overnight Price: $4.31
Wilsons rates ((SHV)) as Overweight (1) –
Select Harvests has confirmed its FY24 outlook for crop volumes of 30,000t at the AGM and increased its financial targets. Wilsons welcomes greater clarity on volumes although notes determining the quality is still several months away.
The prospect of more normal yields and further improvement in the spot almond price should be important drivers of earnings and cash flow and the broker is encouraged by the company's initiatives, retaining an Overweight rating. Target is $5.53.
This report was published on March 1, 2024.
Target price is $5.53 Current Price is $4.31 Difference: $1.22
If SHV meets the Wilsons target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $5.07, suggesting upside of 17.6%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 215.50.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 60.7.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 37.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.37.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.1, implying annual growth of 183.1%.
Current consensus DPS estimate is 3.0, implying a prospective dividend yield of 0.7%.
Current consensus EPS estimate suggests the PER is 21.4.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SPK SPARK NEW ZEALAND LIMITED
Telecommunication – Overnight Price: $4.69
Jarden rates ((SPK)) as Neutral (3) –
Jarden found the first half result from Spark New Zealand in line, noting guidance was maintained. The broker expects ongoing moderate earnings growth but notes the risks on free cash flow translation, given increasing use of leases and the need to consider total investment.
Other risks include mobile, IT services and the company's execution on increasing data centre investment. Neutral retained. Target is raised to NZ$5.12 from NZ$4.95.
This report was published on February 28, 2024.
Current Price is $4.69. Target price not assessed.
Current consensus price target is $4.50, suggesting downside of -4.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 25.50 cents and EPS of 22.63 cents.
At the last closing share price the estimated dividend yield is 5.44%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.73.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.8, implying annual growth of N/A.
Current consensus DPS estimate is 25.9, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 20.6.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 25.96 cents and EPS of 24.57 cents.
At the last closing share price the estimated dividend yield is 5.54%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.09.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.1, implying annual growth of 5.7%.
Current consensus DPS estimate is 26.4, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 19.5.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SPR SPARTAN RESOURCES LIMITED
Gold & Silver – Overnight Price: $0.63
Canaccord Genuity rates ((SPR)) as Speculative Buy (1) –
Canaccord Genuity sees potential for the Never Never gold deposit (at the Spartan Resources' Dalgaranga project in WA) to grow to over 1.5moz, following recent high-grade intercepts, extending the deposit to an around 1km depth.
The broker currently assumes first production in the 2H of FY25, with Never Never underground accounting for 75% of the ounces produced over a seven-year mine life.
The Speculative Buy rating and 75c target are retained.
This report was published on March 5, 2024.
Target price is $0.75 Current Price is $0.63 Difference: $0.12
If SPR meets the Canaccord Genuity target it will return approximately 19% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SXL SOUTHERN CROSS MEDIA GROUP LIMITED
Print, Radio & TV – Overnight Price: $0.96
Canaccord Genuity rates ((SXL)) as Hold (3) –
Southern Cross Media's results were generally below Canaccord Genuity's expectations due to higher costs than anticipated, but the announcement of $30m of cost savings shores up earnings estimates for future periods.
The proposed transaction with ARN Media ((A1N)) and Anchorage Capital Partners continues to move at a funeral pace. The broker considers Southern Cross to be in limbo until a deal does or doesn't happen.
For a revised target price, Canaccord tethers its Southern Cross valuation to ARN's, remaining at Hold, but with an increased target
price of 94c from 85c.
This report was published on March 8, 2024.
Target price is $0.94 Current Price is $0.96 Difference: minus $0.025 (current price is over target).
If SXL meets the Canaccord Genuity target it will return approximately minus 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $1.02, suggesting upside of 5.7%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 4.50 cents and EPS of 6.30 cents.
At the last closing share price the estimated dividend yield is 4.66%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.32.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.2, implying annual growth of -19.8%.
Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 3.8%.
Current consensus EPS estimate suggests the PER is 15.6.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 7.50 cents and EPS of 9.90 cents.
At the last closing share price the estimated dividend yield is 7.77%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.75.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 8.0, implying annual growth of 29.0%.
Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 5.9%.
Current consensus EPS estimate suggests the PER is 12.1.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TRJ TRAJAN GROUP HOLDINGS LIMITED
Medical Equipment & Devices – Overnight Price: $1.02
Canaccord Genuity rates ((TRJ)) as Buy (1) –
Trajan Group's 1H result displayed worse ongoing softness through both quarters than disclosed at the company's AGM last October, notes Canaccord Genuity. Revenue missed the broker's forecast and the 39.7% gross margin fell short of the 41% expected.
While management expects 2H growth and an improvement in the 2H normalised gross margin to 44%, FY24 guidance for revenue was downgraded by -5.7%. Core normalised EBITDA guidance was also downgraded to between $22.3-23.7m.
Longer-term, Canaccord expects a gross margin in the 50% range and an operating EBITDA margin of around 20%. The Buy rating is maintained, though the broker is cautious the stock has entered “value trap” territory.
The target falls to $1.40 from $2.25 on revised near-term growth assumptions.
This report was published on February 29, 2024.
Target price is $1.40 Current Price is $1.02 Difference: $0.375
If TRJ meets the Canaccord Genuity target it will return approximately 37% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 4.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 22.28.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 36.61.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
VGL VISTA GROUP INTERNATIONAL LIMITED
Software & Services – Overnight Price: $1.57
Jarden rates ((VGL)) as Overweight (2) –
Vista International posted a 2023 result that was in line with guidance. Jarden highlights the cost control, with the company delivering on targets, which bodes well for positive free cash flow in the fourth quarter of 2024.
Announcements regarding cloud customers have provided product validity amid site volatility, the broker adds.
Jarden reiterates an Overweight rating and believes if a sufficient recurring revenue run rate and positive cash flow are achieved by the end of the year, this should establish the credibility of the company's strategy. Target is raised to NZ$2.05 from NZ$2.00.
This report was published on February 28, 2024.
Current Price is $1.57. Target price not assessed.
The company's fiscal year ends in December.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 0.28 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 564.75.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.41 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 65.12.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
WGX WESTGOLD RESOURCES LIMITED
Gold & Silver – Overnight Price: $2.48
Canaccord Genuity rates ((WGX)) as Buy (1) –
Westgold Resources' first half earnings result, featuring a 40% margin, was in line with Canaccord Genuity's forecasts, representing a 132% increase year on year. The broker was not expecting the 1c dividend.
Management has reiterated FY24 production and cost guidance and growth capex guidance is also unchanged.
Based on the first half results, annualised rates are tracking modestly below the low end for production guidance and above the top-end cost range, the broker notes, which does put some pressure on to improve performance in the second half.
Buy and $2.75 target retained.
This report was published on March 8, 2024.
Target price is $2.75 Current Price is $2.48 Difference: $0.27
If WGX meets the Canaccord Genuity target it will return approximately 11% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Canaccord Genuity forecasts a full year FY24 dividend of 2.00 cents and EPS of 22.00 cents.
At the last closing share price the estimated dividend yield is 0.81%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.27.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 2.00 cents and EPS of 38.00 cents.
At the last closing share price the estimated dividend yield is 0.81%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.53.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Petra Capital rates ((WGX)) as Buy (1) –
First half revenue from Westgold Resources reached a record $363m and EBITDA was also a record at $145m amid a continued focus on cost management. A maiden dividend of one cent was declared.
Petra Capital notes the business is currently developing three growth projects plus running aggressive exploration drilling programs over highly prospective tenements, and there is scope for a significant lift in distributions to shareholders based on a forecast strong free cash flow profile.
Buy rating maintained and the target rises to $2.42 from $2.37.
This report was published on March 1, 2024.
Target price is $2.42 Current Price is $2.48 Difference: minus $0.06 (current price is over target).
If WGX meets the Petra Capital target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company's fiscal year ends in June.
Forecast for FY24:
Petra Capital forecasts a full year FY24 dividend of 3.00 cents and EPS of 17.10 cents.
At the last closing share price the estimated dividend yield is 1.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.50.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 9.00 cents and EPS of 24.20 cents.
At the last closing share price the estimated dividend yield is 3.63%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.25.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
XRO XERO LIMITED
Accountancy – Overnight Price: $134.00
Goldman Sachs rates ((XRO)) as Buy (1) –
Xero has updated on its FY25-27 strategy, with a focus on core accounting, payments and payroll in Australia, the US and UK.
Goldman Sachs observes the business is increasingly positive about the financial outlook and product releases have dramatically accelerated across all divisions over the past year.
The broker is also impressed with the commitment to a seamless customer experience and improving mix in the partner channel. Buy rating retained. Target rises to $152 from $141.
This report was published on February 29, 2024.
Target price is $152.00 Current Price is $134.00 Difference: $18
If XRO meets the Goldman Sachs target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $126.48, suggesting downside of -5.6%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 0.00 cents and EPS of 99.22 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 135.05.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 69.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 193.4.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 0.00 cents and EPS of 137.24 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 97.64.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 114.9, implying annual growth of 65.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 116.6.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Wilsons rates ((XRO)) as Overweight (1) –
Xero has reiterated guidance at its investor briefing, with Wilsons observing a "clear strategy" to focus on core offerings in key markets. Following the update, the broker is increasingly keen about the next couple of years.
The company also envisages upside from the arrival of GenAI, which it believes can increase profitability through prompting the user, for example, to add a late payment fee for a "serial late payer".
Wilsons has an Overweight rating and $126.93 target.
This report was published on March 1, 2024.
Target price is $126.93 Current Price is $134.00 Difference: minus $7.07 (current price is over target).
If XRO meets the Wilsons target it will return approximately minus 5% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $126.48, suggesting downside of -5.6%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY24:
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 138.17 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 96.98.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 69.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 193.4.
Forecast for FY25:
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 215.69 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 62.13.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 114.9, implying annual growth of 65.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 116.6.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: 360 - LIFE360 INC
For more info SHARE ANALYSIS: A1N - ARN MEDIA LIMITED
For more info SHARE ANALYSIS: ALC - ALCIDION GROUP LIMITED
For more info SHARE ANALYSIS: ATG - ARTICORE GROUP LIMITED
For more info SHARE ANALYSIS: CAA - CAPRAL LIMITED
For more info SHARE ANALYSIS: CAJ - CAPITOL HEALTH LIMITED
For more info SHARE ANALYSIS: CMM - CAPRICORN METALS LIMITED
For more info SHARE ANALYSIS: CTM - CENTAURUS METALS LIMITED
For more info SHARE ANALYSIS: CUV - CLINUVEL PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: CVN - CARNARVON ENERGY LIMITED
For more info SHARE ANALYSIS: DGL - DGL GROUP LIMITED
For more info SHARE ANALYSIS: DSE - DROPSUITE LIMITED
For more info SHARE ANALYSIS: DSK - DUSK GROUP LIMITED
For more info SHARE ANALYSIS: DUG - DUG TECHNOLOGY LIMITED
For more info SHARE ANALYSIS: EOS - ELECTRO OPTIC SYSTEMS HOLDINGS LIMITED
For more info SHARE ANALYSIS: EVO - EMBARK EARLY EDUCATION LIMITED
For more info SHARE ANALYSIS: FFM - FIREFLY METALS LIMITED
For more info SHARE ANALYSIS: FLT - FLIGHT CENTRE TRAVEL GROUP LIMITED
For more info SHARE ANALYSIS: GDG - GENERATION DEVELOPMENT GROUP LIMITED
For more info SHARE ANALYSIS: GEM - G8 EDUCATION LIMITED
For more info SHARE ANALYSIS: GNC - GRAINCORP LIMITED
For more info SHARE ANALYSIS: GNX - GENEX POWER LIMITED
For more info SHARE ANALYSIS: HVN - HARVEY NORMAN HOLDINGS LIMITED
For more info SHARE ANALYSIS: IPD - IMPEDIMED LIMITED
For more info SHARE ANALYSIS: IR1 - IRIS METALS LIMITED
For more info SHARE ANALYSIS: JLG - JOHNS LYNG GROUP LIMITED
For more info SHARE ANALYSIS: KAR - KAROON ENERGY LIMITED
For more info SHARE ANALYSIS: KED - KEYPATH EDUCATION INTERNATIONAL INC
For more info SHARE ANALYSIS: KYP - KINATICO LIMITED
For more info SHARE ANALYSIS: LBL - LASERBOND LIMITED
For more info SHARE ANALYSIS: LNW - LIGHT & WONDER INC
For more info SHARE ANALYSIS: M7T - MACH7 TECHNOLOGIES LIMITED
For more info SHARE ANALYSIS: MAQ - MACQUARIE TECHNOLOGY GROUP LIMITED
For more info SHARE ANALYSIS: MDR - MEDADVISOR LIMITED
For more info SHARE ANALYSIS: MEI - METEORIC RESOURCES NL
For more info SHARE ANALYSIS: MOZ - MOSAIC BRANDS LIMITED
For more info SHARE ANALYSIS: MXI - MAXIPARTS LIMITED
For more info SHARE ANALYSIS: NEU - NEUREN PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: NXD - NEXTED GROUP LIMITED
For more info SHARE ANALYSIS: NXS - NEXT SCIENCE LIMITED
For more info SHARE ANALYSIS: NXT - NEXTDC LIMITED
For more info SHARE ANALYSIS: ORI - ORICA LIMITED
For more info SHARE ANALYSIS: PPG - PRO-PAC PACKAGING LIMITED
For more info SHARE ANALYSIS: PPM - PEPPER MONEY LIMITED
For more info SHARE ANALYSIS: PPT - PERPETUAL LIMITED
For more info SHARE ANALYSIS: PTM - PLATINUM ASSET MANAGEMENT LIMITED
For more info SHARE ANALYSIS: QOR - QORIA LIMITED
For more info SHARE ANALYSIS: RED - RED 5 LIMITED
For more info SHARE ANALYSIS: RHC - RAMSAY HEALTH CARE LIMITED
For more info SHARE ANALYSIS: S32 - SOUTH32 LIMITED
For more info SHARE ANALYSIS: SDR - SITEMINDER LIMITED
For more info SHARE ANALYSIS: SHV - SELECT HARVESTS LIMITED
For more info SHARE ANALYSIS: SLR - SILVER LAKE RESOURCES LIMITED
For more info SHARE ANALYSIS: SPK - SPARK NEW ZEALAND LIMITED
For more info SHARE ANALYSIS: SPR - SPARTAN RESOURCES LIMITED
For more info SHARE ANALYSIS: STO - SANTOS LIMITED
For more info SHARE ANALYSIS: SXL - SOUTHERN CROSS MEDIA GROUP LIMITED
For more info SHARE ANALYSIS: TRJ - TRAJAN GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: VGL - VISTA GROUP INTERNATIONAL LIMITED
For more info SHARE ANALYSIS: WGX - WESTGOLD RESOURCES LIMITED
For more info SHARE ANALYSIS: XRO - XERO LIMITED